Ozdemir, O. Et Al. 2022. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. ANTI-CANCER DRUGS , vol.33, no.7 , 663-670.

Ozdemir, O., Zengel, B., Yildiz, Y., Uluc, B. O., ÇABUK, D., Ozden, E., ... Salim, D. K.(2022). The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. ANTI-CANCER DRUGS , vol.33, no.7, 663-670.

Ozdemir, Ozlem Et Al. "The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study," ANTI-CANCER DRUGS , vol.33, no.7, 663-670, 2022

Ozdemir, Ozlem Et Al. "The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study." ANTI-CANCER DRUGS , vol.33, no.7, pp.663-670, 2022

Ozdemir, O. Et Al. (2022) . "The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study." ANTI-CANCER DRUGS , vol.33, no.7, pp.663-670.

@article{article, author={Ozlem Ozdemir Et Al. }, title={The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study}, journal={ANTI-CANCER DRUGS}, year=2022, pages={663-670} }